BACKGROUND: The human EGF receptor (EGFR or HER) family and its cognate ligands contribute significantly to the aggressiveness of many human malignancies, and are therefore therapeutic targets with great clinical potential. OBJECTIVE: Currently approved single-targeted agents, like mAbs, (e.g., trastuzumab, cetuximab, or pertuzumab) or small-molecule tyrosine kinase inhibitors (TKIs, e.g., gefinitib and erlotinib), are limited by their exquisite specificity (mAbs) or lack thereof (TKIs). Therefore, therapeutics are needed that target multiple HER family members and HER ligands to circumvent these limitations. METHODS: We summarize therapeutic mechanisms of action, analyze tumor resistance to current anti-HER therapies, and introduce a novel pan-HER ligand sequestering agent for cancer treatment. CONCLUSION: RB200, a bispecific (EGFR/HER3) ligand binding trap, has been developed to address the need for a pan-HER therapy in human cancer.
BACKGROUND: The humanEGF receptor (EGFR or HER) family and its cognate ligands contribute significantly to the aggressiveness of many human malignancies, and are therefore therapeutic targets with great clinical potential. OBJECTIVE: Currently approved single-targeted agents, like mAbs, (e.g., trastuzumab, cetuximab, or pertuzumab) or small-molecule tyrosine kinase inhibitors (TKIs, e.g., gefinitib and erlotinib), are limited by their exquisite specificity (mAbs) or lack thereof (TKIs). Therefore, therapeutics are needed that target multiple HER family members and HER ligands to circumvent these limitations. METHODS: We summarize therapeutic mechanisms of action, analyze tumor resistance to current anti-HER therapies, and introduce a novel pan-HER ligand sequestering agent for cancer treatment. CONCLUSION: RB200, a bispecific (EGFR/HER3) ligand binding trap, has been developed to address the need for a pan-HER therapy in humancancer.
Authors: Klaus Koefoed; Lucilla Steinaa; Josefine Nielsen Søderberg; Ida Kjær; Helle Jane Jacobsen; Per-Johan Meijer; John Sørensen Haurum; Allan Jensen; Michael Kragh; Peter Sejer Andersen; Mikkel Wandahl Pedersen Journal: MAbs Date: 2011-11-01 Impact factor: 5.857
Authors: Menghong Sun; Carmen Behrens; Lei Feng; Natalie Ozburn; Ximing Tang; Guosheng Yin; Ritsuko Komaki; Marileila Varella-Garcia; Waun Ki Hong; Kenneth D Aldape; Ignacio I Wistuba Journal: Clin Cancer Res Date: 2009-07-21 Impact factor: 12.531
Authors: Shyhmin Huang; Chunrong Li; Eric A Armstrong; Chimera R Peet; Jarob Saker; Lukas C Amler; Mark X Sliwkowski; Paul M Harari Journal: Cancer Res Date: 2012-11-20 Impact factor: 12.701
Authors: Luisa Paris; Serena Cecchetti; Francesca Spadaro; Laura Abalsamo; Luana Lugini; Maria Elena Pisanu; Egidio Iorio; Pier Giorgio Natali; Carlo Ramoni; Franca Podo Journal: Breast Cancer Res Date: 2010-05-12 Impact factor: 6.466
Authors: Luke L Gompels; Nasser M Malik; Leigh Madden; Pei Jin; Marc Feldmann; H Michael Shepard; Ewa M Paleolog Journal: Arthritis Res Ther Date: 2011-10-07 Impact factor: 5.156